RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Citius Pharmaceuticals Stock

Citius Pharmaceuticals P/S 2024

Citius Pharmaceuticals P/S

0

Ticker

CTXR

ISIN

US17322U2078

WKN

A2DXS0

As of Dec 18, 2024, Citius Pharmaceuticals's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Citius Pharmaceuticals P/S history

Citius Pharmaceuticals Aktienanalyse

What does Citius Pharmaceuticals do?

Citius Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for unmet medical needs. The company was founded in 2006 and is headquartered in Cranford, New Jersey. Business Model Citius Pharmaceuticals' business model is based on the development of drugs and therapies for rare and unmet medical needs. The company utilizes its industry experience and knowledge to identify unmet medical needs and develop novel therapeutic approaches. Citius Pharmaceuticals collaborates closely with leading academic and scientific institutions to expedite and enhance the effectiveness of its development projects. History Citius Pharmaceuticals was founded by Myron Holubiak, who has over 30 years of experience in the pharmaceutical and biotech industry. Holubiak previously led drug development efforts for companies such as 3M Pharmaceuticals and Elan Pharmaceuticals. In 2007, Citius Pharmaceuticals went public to raise capital for its development projects. Products and Divisions Citius Pharmaceuticals operates in two main divisions: the first focuses on the development of drugs for rare and unmet medical needs, while the second concentrates on the development of therapies for common conditions such as hemorrhoids and cold sores. One of Citius Pharmaceuticals' products is Mino-Lok®, a medication for the treatment of severe intravenous catheter infections. This product is designed to reduce the need for antibiotics commonly used in such infections. Mino-Lok® is currently in Phase III clinical development. Another product by Citius Pharmaceuticals is Halo-Lido, a new therapy for hemorrhoids. It contains lidocaine and hydrocortisone acetate, and is developed to reduce pain and inflammation associated with hemorrhoids. Halo-Lido has already been approved by the US Food and Drug Administration (FDA) and is currently available on the market. Additionally, Citius Pharmaceuticals has a portfolio of patented and trademarked products that provide a platform for future growth. The company is also working on the development of new therapies for cold sores and other viral infections. Conclusion Citius Pharmaceuticals Inc. is an innovative biopharmaceutical company that identifies the needs of unmet medical areas and develops innovative solutions for treating these conditions. With an experienced management team and a strong portfolio of patented products, Citius Pharmaceuticals is well positioned to continue growing and increasing value for its stakeholders. Citius Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Citius Pharmaceuticals's P/S Ratio

Citius Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Citius Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Citius Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Citius Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Citius Pharmaceuticals stock

What is the price-to-earnings ratio of Citius Pharmaceuticals?

The price-earnings ratio of Citius Pharmaceuticals is currently 0.

How has the price-earnings ratio of Citius Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Citius Pharmaceuticals has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Citius Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Citius Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Citius Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Citius Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Citius Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Citius Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Citius Pharmaceuticals?

Some factors that influence the price-earnings ratio of Citius Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Citius Pharmaceuticals pay?

Over the past 12 months, Citius Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Citius Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Citius Pharmaceuticals?

The current dividend yield of Citius Pharmaceuticals is .

When does Citius Pharmaceuticals pay dividends?

Citius Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Citius Pharmaceuticals?

Citius Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Citius Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Citius Pharmaceuticals located?

Citius Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Citius Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Citius Pharmaceuticals from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Citius Pharmaceuticals pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Citius Pharmaceuticals in the year 2023?

In the year 2023, Citius Pharmaceuticals distributed 0 USD as dividends.

In which currency does Citius Pharmaceuticals pay out the dividend?

The dividends of Citius Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Citius Pharmaceuticals

Our stock analysis for Citius Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Citius Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.